Tonix enrolls first patient in Phase 2 MDD study of TNX-102 SL
Tweet Send to a Friend
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that the first patient has been enrolled in HORIZON, a Phase 2 clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


